|Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.|
1. Intravenous acetaminophen (Ofirmev). Med Lett Drugs Ther 2011; 53:26.
2. Acetaminophen safety - Deja vu. Med Lett Drugs Ther 2009; 51:53.
3. PB Watkins et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296:87.
4. Addendum: warfarin-acetaminophen interaction. Med Lett Drugs Ther 2008; 50:45.
5. In brief: does acetaminophen increase blood pressure? Med Lett Drugs Ther 2011; 53:29.
6. PL McCormack. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 2011; 71:2457.
7. Primary prevention of ulcers in patients taking aspirin or NSAIDs. Med Lett Drugs Ther 2010; 52:17.
8. Naproxen/esomeprazole (Vimovo). Med Lett Drugs Ther 2010; 52:74.
9. A fixed-dose combination of ibuprofen and famotidine (Duexis). Med Lett Drugs Ther 2011; 53:85.
10. S Trelle et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.
11. P McGettigan and D Henry. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8:e1001098.
12. ME Farkouh and BP Greenberg. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009; 103:1227.
13. WB White et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99:91.
14. EM Antman et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115:1634.
15. E Cho et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 2011; 171:1487.
16. CM Reid et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:837.
17. TJ Cicero et al. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367:187.
18. In brief: immediate-release oxycodone (Oxecta) for pain. Med Lett Drugs Ther 2012; 54:20.
19. Oral oxymorphone (Opana). Med Lett Drugs Ther 2007; 49:3.
20. PA Sloan and R Barkin. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag 2008; 4:131.
21. Extended-release hydromorphone (Exalgo) for pain. Med Lett Drugs Ther 2011; 53:62.
22. H Binsfeld et al. A randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010; 10:404.
23. In brief: heat and transdermal fentanyl. Med Lett Drugs Ther 2009; 51:64.
24. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.
25. FDA. FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems ("patches"). April 18, 2012. Available at www.fda.gov/Drugs/DrugSafety/ucm300747.htm.
26. JS Morley et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med 2003; 17:576.
27. MC Rowbotham et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348:1223.
28. KM Foley. Opioids and chronic neuropathic pain. N Engl J Med 2003; 348:1279.
29. E Bruera et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185.
30. GB Ehret et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280.
31. MJ Krantz et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.
32. FDA. FDA Drug Safety Communication: safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and /or adenoidectomy. February 20, 2013. Available at www.fda.gov/Drugs/DrugSafety/ucm339112.htm. Accessed March 7, 2013.
33. Tapentadol (Nucynta) – a new analgesic. Med Lett Drugs Ther 2009; 51:61.
34. M Afilalo and B Morlion. Efficacy of tapentadol ER for managing moderate to severe pain. Pain Physician 2013; 16:27.
35. RM Duhmke et al. Tramadol for neuropathic pain (review). Cochrane Database Syst Rev 2004; (2):CD003726.
36. Transdermal buprenorphone (Butrans) for chronic pain. Med Lett Drugs Ther 2011; 53:31.
37. Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.
38. New indications for modafinil (Provigil). Med Lett Drugs Ther 2004; 46:34.
39. Methylnaltrexone (Relistor) for opioid-induced constipation. Med Lett Drugs Ther 2008; 50:63.
40. J Thomas et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332.
41. MJ Brennan. The effect of opioid therapy on endocrine function. Am J Med 2013; 126:S12.
42. K Bannister and AH Dickenson. Opioid hyperalgesia. Curr Opin Support Palliat Care 2010; 4:1.
43. I Gilron et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374:1252.
44. W Häuser et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301:198.
45. SH Sindrup et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96:399.
46. DR Grothe et al. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004; 24:621.
47. Duloxetine (Cymbalta) for diabetic neuropathic pain. Med Lett Drugs Ther 2005; 47:67.
48. Duloxetine (Cymbalta) for fibromyalgia. Med Lett Drugs Ther 2008; 50:57.
49. Duloxetine (Cymbalta) for chronic musculoskeletal pain. Med Lett Drugs Ther 2011; 53:33.
50. Milnacipran (Savella) for fibromyalgia. Med Lett Drugs Ther 2009; 51:45.
51. Gabapentin (Neurontin) for chronic pain. Med Lett Drugs Ther 2004; 46:29.
52. I Gilron et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352:1324.
53. Pregabalin (Lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther 2005; 47:75.
54. W Häuser et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin—a meta-analysis of randomized controlled trials. Pain 2009; 145:69.
55. Ziconotide (Prialt) for chronic pain. Med Lett Drugs Ther 2005; 47:103.
56. RY Yuan et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72:1473.
57. Medical marijuana. Med Lett Drugs Ther 2010; 52:5.
58. M Karst et al. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010; 70:18.
59. PS Davies and BS Galer. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64:937.
60. Capsaicin patch (Qutenza) for postherpetic neuralgia. Med Lett Drugs Ther 2011; 53:42.
61. FDA. FDA drug safety communication: rare cases of serious burns with the use of over-the-counter topical muscle and joint pain relievers. Available at www.fda.gov/Drugs/DrugSafety/ucm318858.htm. Accessed March 8, 2013.